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INTRODUCTION
Patients with advanced-stage, low-grade non-Hodgkin’s
lymphoma (NHL) have a variable but usually long natural
history, with a median survival of 6–10 years after diagnosis
[1]. A major cause of morbidity and mortality in this group of
patients is transformation of the low-grade lymphoma to one
with a diffuse aggressive histology, with median survival after
histologic conversion in most series of <2 years for patients
with follicular lymphoma and ~5 months for patients with
chronic lymphocytic leukemia [1–10]. The incidence of his-
tologic transformation increases with time and ranges from 3
to 10% for patients with chronic lymphocytic leukemia
(CLL) or small lymphocytic lymphoma and from 10 to 70%
for patients with follicular lymphoma [10–18].
Results of conventional therapy for patients who have
undergone histologic transformation have varied. Several
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ABSTRACT
The role of high-dose therapy and autologous stem cell transplantation in diffuse large B cell lymphoma (DLBCL)
after transformation is controversial. We have retrospectively analyzed patients with chemosensitive disease and a
history of follicular lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma who underwent high-
dose chemoradiotherapy and bone marrow transplantation (BMT) with anti–B cell monoclonal antibody–purged
autologous marrow for DLBCL. Between December 1982 and August 1997, 27 patients underwent autologous
BMT using a uniform ablative regimen with cyclophosphamide, total-body irradiation, and bone marrow purging.
All patients received multiple chemotherapy regimens before autologous BMT. At bone marrow (BM) harvest, only
44% of patients were in complete remission, and overt BM infiltration was present in 37%. After cyclophosphamide
and total-body irradiation, no treatment-related deaths were seen. Eleven of the 27 patients relapsed, and four
patients developed myelodysplasia/acute myelogenous leukemia. In seven patients in whom pathologic studies were
available after relapse, the histology remained DLBCL. Twelve patients remained alive and in complete remission
with a median follow-up of 36 months (range 10–132). The disease-free survival and overall survival are estimated
to be 46% (90% confidence interval 28–64) and 58% (40–76) at 5 years, respectively. Patients whose disease under-
went histologic transformation within 18 months of their initial diagnosis of indolent lymphoma had significantly
better overall survival. Selected patients with histologic transformation, particularly those whose transformation
occurs early in the course of their disease and who remain chemosensitive, may experience prolonged survival after
autoBMT.
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series suggested a uniformly poor response to chemotherapy
and a short remission duration and survival [2,7–9,13,14,16].
Selected patients who achieve a complete remission (CR)
with combination chemotherapy can experience prolonged
survival, however. In two recent reports, the median sur-
vivals for patients achieving CR were 42 and 81 months,
respectively [4,19]. Factors that adversely influenced survival
included advanced stage, previous therapy, elevated lactate
dehydrogenase (LDH), bone marrow involvement, B symp-
toms, and lack of CR in response to therapy.
The combination of high-dose therapy and autologous
stem cell transplantation (autoSCT) has been shown to
improve both disease-free and overall survival for selected
patients with relapsed intermediate-grade lymphoma [20]. A
relatively limited number of patients with histologic trans-
formation from indolent NHL to diffuse large B cell NHL
have been reported to have undergone autoSCT [21–24]. In
two of these studies, the long-term survival was <20%, com-
plicated by both high treatment-related mortality and
relapse [21,22]. In the present study, we report the results of
27 selected patients with a history of indolent B cell NHL
or CLL whose disease transformed to DLBCL and who
remained chemosensitive and were able to obtain a minimal
disease state. These patients were uniformly treated with
high-dose chemoradiotherapy and autoBMT with anti–B
cell monoclonal antibody–treated marrow. In the results
reported below, we demonstrate that the 5-year disease-free
survival (DFS) and overall survival (OS) are 46 and 58%,
respectively. Moreover, the median overall survival from the
time of transformation is 130 months. This study suggests
that a subset of patients whose disease has undergone histo-
logic transformation may experience prolonged survival
after autoBMT.
MATERIALS AND METHODS
Selection of patients and treatment protocol
Patients were eligible for this study if they were <65
years old and had a history of diffuse small lymphocytic
lymphoma/CLL or follicular small cleaved cell or follicular
mixed NHL as defined by the International Working For-
mulation (WF A, B, or C) or follicular center cell lymphoma
grade I or II (in the Revised European-American Lym-
phoma [REAL] classification) that transformed to DLBCL
[25,26]. Patients with discordant histology on presentation
or whose transformation occurred within 6 months of diag-
nosis were excluded. All patients had relapsed after standard
chemotherapeutic regimens. Lymphoma cells expressed the
CD20 (B1) antigen as previously described [23,27]. For all
patients, a minimal disease status had to be attained through
chemotherapy, radiotherapy, or both before entry. This sta-
tus was defined as lymph node masses <2 cm and histologic
evidence of bone marrow (BM) involvement of ≤20% of the
intratrabecular space as determined by iliac crest biopsy.
Additional criteria for entry were described previously [23].
Preparative therapy consisted of 60 mg/kg cyclophos-
phamide infused on each of 2 consecutive days before radio-
therapy. Total-body irradiation (TBI) was administered in
fractionated doses (200 cGy) twice daily on 3 consecutive
days (total of 1200 cGy) in 18 patients; nine patients
received 1400 cGy in seven fractions. Granulocyte or granu-
locyte-macrophage colony-stimulating factor (G-CSF or
GM-CSF) was administered to 16 patients. Supportive care
was provided as previously described [23].
Collection, processing, and infusion of marrow
BM was obtained, treated in vitro, and stored as previ-
ously described [23]. No patients were excluded from the
protocol after BM harvest. The BM cells from seven
patients were treated with anti-B1 (CD20) monoclonal anti-
body. The BM cells from 20 patients were treated with
more than one monoclonal antibody, including 14 with anti-
B1, anti-B5, and J5 (anti-CD10); four with anti-B1, -B4
(CD19), -B5, and J5 (anti-CD10); and two with a combina-
tion of anti-B1 and anti-B5. After treatment, the cells were
cryopreserved as previously described. Within 24 hours of
the completion of radiotherapy, the cryopreserved BM cells
were rapidly thawed and diluted in medium containing
DNase as previously described [23]. The median number of
cells infused was 4.623107/kg (range 1.47–9.463107).
PCR analysis
Nested polymerase chain reaction (PCR) amplification
at the major breakpoint region (MBR) and minor cluster
region (mcr) of the bcl-2/IgH rearrangement of t(14;18) was
performed as previously described [28]. Analysis was per-
formed initially on diagnostic material (lymph node biopsy
and BM aspirate if BM was involved histologically). Samples
were analyzed at the time of BM harvest. Assessment was
also performed after ex vivo marrow purging.
Evaluation and statistical methods
Failure was defined as relapse of disease or death during
remission. DFS was calculated from the day of marrow rein-
fusion (day 0) to the day of failure or the date when the
patient was last known to be alive and disease free. OS was
calculated from the day of marrow reinfusion until death or
the date when the patient was last known to be alive. DFS
curves and time-to-relapse curves were estimated by the
method of Kaplan and Meier, with confidence intervals (CI)
calculated using Greenwood’s formula and compared by the
log-rank test [29,30]. The Cox proportional hazards model
was used to assess prognostic factors for time to relapse and
DFS and to attempt to build multiple regression models.
RESULTS
Patient characteristics
Twenty-seven patients with a history of indolent NHL
in which the histology had transformed to DLBCL under-
went autoBMT between December 1982 and August 1997.
Before histologic transformation, 15 patients had follicular
center cell grade I, six had follicular center cell grade II, and
six had CLL/small lymphocytic lymphoma. The characteris-
tics of these 27 patients before autoBMT are detailed in
Table 1. The median age of these patients was 44 years
(range 29–58). At the time of diagnosis of DLBCL, all
patients had stage IV disease by virtue of BM involvement
(18 patients) or extranodal sites exclusive of the BM, includ-
ing skin, peripheral blood, gastrointestinal tract, and pleural
and peritoneal fluid (15 patients). Two patients had
immunoblastic histology. The median time from diagnosis
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of indolent NHL/CLL to histologic conversion was 35
months (range 6–184), and the median time from transfor-
mation to autoBMT was 9 months (range 2–41). The medi-
an time from diagnosis to autoBMT was 43 months.
Prior therapy
All patients had previously received combination
chemotherapy. The median number of regimens with which
patients were treated was three (range two to 10). Eleven
patients had received local radiation to sites of bulk disease
(three after transformation before autoBMT and eight for
low-grade NHL), and one patient had received TBI (150
cGy). At BM harvest, only 12 (44%) of the patients were in
CR. Moreover, of the 15 patients in partial remission (PR)
at harvest, nine had residual BM involvement (six had small
cleaved cells, two had mixed small cleaved and large cells,
and one had large cells in the marrow).
Treatment outcome
No in-hospital deaths occurred among the 27 patients
treated (Table 2). Four patients developed secondary
myelodysplasia syndrome (MDS) or acute myelogenous
leukemia (AML) without evidence of recurrent NHL
between 40 and 120 months after autoBMT. Three of these
patients died, two from complications of allogeneic BM
transplantation. Of the remaining 23 patients, 11 had dis-
ease progression as of September 1998. Twelve patients
remained alive and in CR with a median follow-up of 36
months (range 10–132). The Kaplan-Meier estimate of the
percentage of patients alive and disease free at 5 years is
46% (90% CI 28–64) (Fig. 1A). The Kaplan-Meier estimate
of the OS at 5 years is 58% (40–76) (Fig. 1B).
Of the 11 patients who had relapses, nine had relapses in
sites of previous disease, one had simultaneous relapses in
old and new sites of disease, and one had a relapse only in a
new site. Six of these patients were in PR at harvest, and five
were in CR. Pathologic studies were available in seven of
the 11 patients who had relapses, and all were found to have
DLBCL. After relapse two patients remained alive, one at a
follow-up of 7 months and one at 81 months. The median
OS from first diagnosis of low-grade lymphoma was 151
months (range 22–232), and the median OS from the time
of transformation was 130 months (range 15–138).
PCR analysis after autoBMT
PCR analysis of MBR and mcr of the bcl-2/IgH
rearrangement was performed on BM samples before and
after ex vivo purging. Samples of harvested marrow before
and after ex vivo purging were available for analysis from 10
patients with a history of follicular lymphoma and a known
PCR-amplifiable bcl-2/IgH rearrangement. After immuno-
logic purging, PCR analysis revealed no detectable disease
in five of these patients; in the remaining five patients,
PCR-detectable disease persisted after purging. Among the
five patients who were PCR-negative after purging, two
relapses occurred, and three relapses occurred among the
five patients who were PCR-positive after purging.
Prognostic factors
In an attempt to identify prognostic variables for these
patients, a number of factors—including patient age, sex,
original histology, previous chemotherapy regimens, and dis-
ease status on entrance to transplantation—were examined in
univariate comparison of DFS and OS using the log-rank
test. There were no differences in DFS or OS from
autoBMT for the 12 patients who were in CR at transplanta-
tion compared with the 15 patients in PR (p = 0.17). There
were also no differences in DFS or OS from autoBMT
among the six patients with an initial diagnosis of CLL/small
lymphocytic lymphoma compared with those whose initial
histology was follicular NHL (p = 0.66). Patients whose dis-
ease underwent histologic transformation within 18 months
of their initial diagnosis of indolent NHL/CLL had signifi-
cantly better OS from transformation (p = 0.02) and trans-
plantation (p = 0.04) than did patients transplanted more
than 18 months from initial diagnosis, even though both
groups received a similar number of prior chemotherapy reg-
imens (Fig. 2). The 5-year OS from autoBMT in patients
with early transformation was 80% compared with 31% for
patients whose transformation occurred after 18 months.
Multiple regression models did not identify additional fac-
tors, including patient age, original histology, and disease
status on entrance to transplantation, to explain this differ-
ence in OS. The 5-year DFS in patients with early transfor-
mation was 62% compared with 31% for patients whose
transformation occurred after 18 months. This difference
was not statistically significant at the 0.05 level.
DISCUSSION
The pathogenesis of the histologic transformation of
low-grade lymphoma to DLBCL is not well understood, but
Table 1. Patient characteristics at the time of autoBMT




Median age in years (range) 44 (29–58)
Histology at initial diagnosis 
CLL/small lymphocytic lymphoma 6
Follicular center grade I 15
Follicular center grade II 6
Extranodal disease
Bone marrow Involvement 18





Table 2. Clinical outcome after ABMT
Total number of patients 27
Treatment-associated deaths 0
Continuous clinical remission 12
Disease progression (alive) 11 (2)
Secondary MDS/AML (alive) 4 (1)
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it is thought to represent progression by a single malignant
B cell [11,31–33]. Neoplastic cells in >80% of patients with
follicular lymphoma have the t(14;18) bcl-2/IgH transloca-
tion; however, additional chromosomal abnormalities have
been associated with histologic transformation. Cytogenetic
analysis suggests that follicular lymphoma patients whose
tumor cells have deletions of chromosomes 6p, 17p, and 9p
have a significantly increased risk of transformation [34–37].
Specific genes have been identified as being altered in trans-
formation, including deletions of the cyclin-dependent
kinase inhibitors p15 and p16 and mutations of p53 and bcl-
2. Because the risk of transformation in both follicular NHL
and CLL is reported to be independent of previous therapy,
perhaps these genetic changes are a component of the evo-
lution of follicular lymphoma and not caused by chemo-
therapy, radiation, or both.
The prognosis of patients after histologic conversion
varies but is generally reported to be poor with convention-
al combination chemotherapy. The median survival after
transformation of follicular NHL and CLL in recent series
was only 7 and 5 months, respectively [10,19]. For the sub-
set of patients with follicular NHL who attained a complete
response to chemotherapy after transformation, however,
median survival of 40.5 and 81 months has been reported
Figure 1. Probability of disease-free and overall survival
Kaplan-Meier estimates of probability of DFS (A) and OS ( B) after autoBMT for 27 patients with histologic transformation of indolent lymphoma.
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[4,19]. Other clinical predictors of prolonged survival after
transformation include limited-stage disease at transforma-
tion and no history of chemotherapy before histologic
transformation.
Because high-dose therapy and hematopoietic stem cell
support can prolong DFS and OS in patients with relapsed
diffuse large cell lymphoma [20], this approach has also been
investigated in patients with DLBCL who had a history of
indolent NHL/CLL. Generally, the reports of autoSCT
after histologic transformation have been limited and the
outcome less favorable than that in relapsed diffuse large
cell lymphoma without prior transformation. Nine patients
at the University of Nebraska underwent autoBMT and had
a poor outcome, with six treatment-related deaths and only
one patient in maintained remission at the time of the
report [21]. Most of those patients had bulky disease, and
only four patients had responded to chemotherapy before
transplantation. Bastion et al. [22] reported results of
autoSCT in 16 patients, with outcomes quite similar to
those of the present series in terms of relapse and treatment-
related mortality 
One study found that after conventional therapy for his-
tologic transformation, about half of the patients relapsed
with diffuse large cell lymphoma [4]. Similarly, in the pres-
ent series, most patients for whom pathologic material was
available had diffuse large cell lymphoma after relapse from
autoBMT. This is in contrast to the report by Bastion et al.
[22] in which histology at relapse was predominantly follicu-
lar NHL. The explanation for this difference is not clear,
but it may be caused by the burden of disease at transforma-
tion, drug resistance from pretreatment, or differences in
ablative regimens.
The current series represents the largest single-institu-
tion experience in patients whose disease underwent histo-
logic transformation. With longer follow-up and additional
patients, the present results confirm our previous report [23]
that selected patients whose disease has undergone histolog-
ic transformation have a disease-free survival after autoBMT
similar to that of patients who have relapsed de novo large
cell lymphoma [20,23,27]. Even longer follow-up will be
necessary to establish whether or not autoBMT is curative
in this setting. Although our patients were highly selected
and had no significant comorbid disease, all patients had
advanced-stage disease at histologic transformation, only
44% had achieved a CR with salvage therapy before
autoBMT, and all patients had received at least two chemo-
therapy regimens before histologic transformation. There-
fore, the prognosis of our cohort would be considered unfa-
vorable with conventional chemotherapy alone, using the
criteria identified by the Stanford group [4]. 
In our study, patients whose disease underwent transfor-
mation within the first 18 months of diagnosis experienced a
significantly better OS than did patients whose disease
transformed later in its course. Both groups of patients
received a similar number of prior chemotherapy regimens,
had advanced disease at transformation, and had similar dis-
ease status at autoBMT. Early transformation of low-grade
lymphoma or CLL may represent a distinct biologic entity
that has a more favorable response to high-dose therapy.
Those who present with both CLL and large cell lymphoma
also may be a subset of patients who have a more favorable
prognosis when treated with conventional therapy [10]. The
cytogenetic and molecular profile of this subgroup of
tumors could yield important information about the mecha-
nisms of drug resistance and the events required for trans-
formation to aggressive histology.
One emerging late complication of high-dose therapy in
patients with lymphoma is the development of MDS or sec-
Figure 2. Overall survival after histologic transformation
Kaplan-Meier estimate of probability of OS for patients who underwent histologic transformation within 18 months (n=9) or after 18 months of diagnosis of low-
grade NHL (p = 0.04).
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ondary AML, both of which have a poor prognosis [38–40].
The risk of MDS increases with extensive exposure to
chemotherapy, pretransplantation radiation, and a pro-
longed period between diagnosis and transplantation. In the
present series, four patients (15%) developed MDS or sec-
ondary AML, which is consistent with our experience after
autoBMT for similarly treated patients with relapsed B cell
NHL. It remains unclear whether MDS arises from the
reinfused marrow exposed to chemotherapy before
autoBMT or is a complication of the high-dose chemora-
diotherapy leading to damaged stem cells that were not
ablated. This finding emphasizes the importance of attempt-
ing to minimize therapy before autoBMT. Moreover, con-
tinued improvements in induction and ablative regimens
also may decrease the incidence of MDS.
Clearly, a subset of patients with histologic transforma-
tion of low-grade lymphoma have a relatively favorable
prognosis. Patients who fulfill the Stanford criteria of CR
after transformation, limited-stage disease at transforma-
tion, and no chemotherapy before transformation have a
reasonable prognosis and can probably be managed with
chemotherapy and observation. Considering that at least
half of the patients with histologic transformation do not
meet these criteria, aggressive therapy with autoBMT is a
sensible treatment option for selected patients, particularly
for those patients whose disease remains chemosensitive and
those whose transformation occurs early in the course of
their disease.
ACKNOWLEDGMENTS
We are indebted to the nurses, adult oncology fellows,
and social workers of the Dana-Farber Cancer Institute and
the house staffs of Brigham and Women’s Hospital and Beth
Israel Hospital for their excellent care of these patients. We
thank the technicians of the Connell-O’Reilly Cell Manipu-
lation Laboratory and the Blood Component Laboratory of
Dana-Farber Cancer Institute for processing of the bone
marrow, the oncologic surgeons of Brigham and Women’s
Hospital and Beth Israel-Deaconess Hospital for their surgi-
cal assistance, and the staffs of the Departments of Radiolo-
gy and Infectious Disease for their assistance in patient care.
We also thank Lisa Warren for secretarial assistance in
preparation of the manuscript.
REFERENCES
1 Horning SJ, Rosenberg SA: The natural history of initially untreated
low-grade non-Hodgkin’s lymphoma. N Engl J Med 311:1471, 1984.
2 Johnson P, Rohatiner A, Whelan J, Price C, Love S, Lim J, Mattews J,
Norton A, Amess J, Lister T: Patterns of survival in patients with recur-
rent follicular lymphoma: a 20 year study from a single center. J Clin
Oncol 13:140, 1995.
3 Gallagher CJ, Gregory WM, Jones AE, Stansfeld AG, Richards MA,
Dhaliwal HS, Malpas JS, Lister TA: Follicular lymphoma: prognostic
factors for response and survival. J Clin Oncol 4:1470, 1986.
4 Yuen A, Kamel O, Halpern J, Horning S: Long-term survival after
histologic transformation of low-grade follicular lymphoma. J Clin
Oncol 13:1726, 1995.
5 Richter M: Generalized reticular cell sarcoma of lymph nodes asso-
ciated with lymphatic leukemia. Am J Pathol 4:285, 1928.
6 Long J, Aisenberg A: Richter’s syndrome. Am J Clin Pathol 63:786,
1975.
7 Armitage J, Dick F, Corder M: Diffuse histiocytic lymphoma com-
plicating chronic lymphocytic leukemia. Cancer 41:422, 1978.
8 Foucar K, Rydell R: Richter’s syndrome in chronic lymphocytic
leukemia. Cancer 46:118, 1980.
9 Harousseau J, Flandrin G, Tricot G, Brouet J, Seligmann M, Bernard
J: Malignant lymphoma supervening in chronic lymphocytic leukemia
and related disorders. Cancer 48:1302, 1981.
10 Robertson L, Pugh W, O’Brien S, Kantarjian H, Hirsch-Ginsberg C,
Cork A, McLaughlin P, Cabanillas F, Keating M: Richter’s syndrome: a
report on 39 patients. J Clin Oncol 11:1985, 1993.
11 Woda B, Knowles D: Nodular lymphocytic lymphoma eventuating
into diffuse histiocytic lymphoma: immunoperoxidase determination of
monoclonality. Cancer 43:303, 1979.
12 Risdall R, Hoppe R, Warnke R: Non-Hodgkin’s lymphoma: a study
of the evolution of the disease based upon 92 autopsied cases. Cancer
44:529, 1979.
13 Trump D, Mann R, Phelps R, Roberts H, Conley C: Richter’s syn-
drome: diffuse histiocytic lymphoma in patients with chronic lympho-
cytic leukemia. Am J Med 68:539, 1980.
14 Armitage JO, Dick FR, Corder MP: Diffuse histiocytic lymphoma
after histologic conversion: a poor prognostic variant. Cancer Treat
Rep 65:413, 1981.
15 Hubbard SM, Chabner BA, DeVita VT, Simon R, Berard CW, Jones
RB, Garvin AJ, Canellos GP, Osborne CK, Young RC: Histologic progres-
sion in non-Hodgkin’s lymphoma. Blood 59:258, 1982.
16 Acker B, Hoppe RT, Colby TV, Cox RS, Kaplan HS, Rosenberg SA:
Histologic conversion in the non-Hodgkin’s lymphomas. J Clin Oncol
1:11, 1983.
17 Garvin A, Simon R, Osborne C, Merrill J, Young R, Berard C: An
autopsy study of histologic progression in non-Hodgkin’s lymphomas.
Cancer 52:393, 1983.
18 Oviatt D, Cousar J, Collins R, Flexner J, Stein R: Malignant lym-
phomas of follicular center cell origin in humans. Cancer 53:1109,
1984.
19 Bastion Y, Sebban C, Berger F, Felman P, Salles G, Dumontet C, Bryon
P, Coiffier B: Incidence, predictive factors, and outcome of lymphoma
transformation in follicular lymphoma patients. J Clin Oncol 15:1587,
1997.
20 Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron
D, Sonneveld P, Gisselbrecht C, Cahn J, Harousseau J, Coiffier B, Biron P,
Mandelli F, Chauvin F: Autologous bone marrow transplantation as
compared with salvage chemotherapy in relapses of chemotherapy-sen-
sitive non-Hodgkin’s lymphoma. N Engl J Med 333:1540, 1995.
21 Schouten HC, Bierman PJ, Vaughan WP, Kessinger A, Vose JM,
Weisenburger DD, Armitage JO: Autologous bone marrow transplanta-
tion in follicular non-Hodgkin’s lymphoma before and after histologic
transformation. Blood 74:2579, 1989.
22 Bastion Y, Brice P, Haioun C, Sonet A, Salles G, Marolleau J,
Espinouse D, Reyes F, Gisselbrecht C, Coiffier B: Intensive therapy with
peripheral blood progenitor cell transplantation in 60 patients with
poor-prognosis follicular lymphoma. Blood 86:3257, 1995.
23 Freedman AS, Ritz J, Neuberg D, Anderson KC, Rabinowe SN, Mauch
P, Takvorian T, Soiffer R, Blake K, Yeap B, Coral F, Helfin L, Nadler LM:
Autologous bone marrow transplantation in 69 patients with a history
of low grade B cell non-Hodgkin’s lymphoma. Blood 77:2524, 1991.
24 Foran J, Apostolidis J, Papamichael D, Norton A, Matthews J, Amess J,
Lister T, Rohatiner A: High-dose therapy with autologous haematopoi-
etic support in patients with transformed follicular lymphoma: a study
of 27 patients from a single centre. Ann Oncol 9:865, 1998.
J.W. Friedberg et al.
268
25 NCI: National Cancer Institute sponsored study of classification of
non-Hodgkin’s lymphomas: summary and description of a working for-
mulation for clinical usage. The non-Hodgkin’s lymphoma classifica-
tion project. Cancer 49:2112, 1982.
26 Harris N, Jaffe E, Stein H, Banks P, Chan J, Cleary M, Delsol G, de
Wolf-Peeters C, Falini B, Gatter K, Grogan T, Isaacson P, Knowles D,
Mason D, Muller-Hermelink H, Pileri S, Piris M, Ralfkiaer E, Warnke R:
Perspective: a revised European American classification of lymphoid
neoplasm: a proposal from the International Lymphoma Study Group.
Blood 84:1361, 1994.
27 Takvorian T, Canellos GP, Ritz J, Freedman AS, Anderson KC, Mauch
P, Tarbell N, Coral F, Daley H, Yeap B, Schlossman SF, Nadler LM: Pro-
longed disease-free survival after autologous bone marrow transplanta-
tion in patients with non-Hodgkin’s lymphoma with poor prognosis. N
Engl J Med 316:1499, 1987.
28 Gribben J, Freedman A, Woo S, Blake K, Shu R, G F, Longtine J,
Pinkus G, Nadler L: All advanced stage non-Hodgkin’s lymphomas with
a polymerase chain reaction amplifiable breakpoint of bcl-2 have resid-
ual cells containing the bcl-2 rearrangement at evaluation and after
treatment. Blood 78:3275, 1991.
29 Kaplan E, Meier P: Nonparametric estimation from incomplete
observations. J Am Stat Assoc 53:457, 1958.
30 Mantel N: Evaluation of survival data and two new rank order sta-
tistics arising in its consideration. Cancer Chemother Rep 50:163,
1966.
31 Zelenetz AD, Chen TT, Levy R: Histologic transformation of follic-
ular lymphoma to diffuse lymphoma represents tumor progression by a
single malignant B cell. J Exp Med 173:197, 1991.
32 Delsol G, Laurent G, Kuhlein E, Familiades J, Rigal F, Pris J:
Richter’s syndrome: evidence for the clonal origin of the two prolifera-
tions. Am Soc Clin Pathol 76:308, 1981.
33 Bertoli L, Kubagawa H, Borzillo G, Mayumi M, Prchal J, Kearney J,
Durant J, Cooper M: Analysis with antiidiotype antibody of a patient
with chronic lymphocytic leukemia and a large cell lymphoma
(Richter’s syndrome). Blood 70:45, 1987.
34 Elenitoba-Johnson K, Gascoyne R, Lim M, Lim M, Chhanabai M, Jaffe
E, Raffeld M: Homozygous deletions at chromosome 9p21 involving
p16 and p15 are associated with histologic progression in follicle center
lymphoma. Blood 91:4677, 1998.
35 Lo Coco F, Gaidano G, Louie D, Offit K, Chaganti R, Dalla-Favera R:
p53 mutations are associated with histologic transformation of follicular
lymphoma. Blood 82:2289, 1993.
36 Tilly H, Rossi A, Stamatoullas A, Lenormand B, Bigorgne C, Kunlin A,
Monconduit M, Bastard C: Prognostic value of chromosomal abnormali-
ties in follicular lymphoma. Blood 84:1043, 1994.
37 Matolcsy A, Casali P, Warnke R, Knowles D: Morphologic transfor-
mation of follicular lymphoma is associated with somatic mutation of
the translocated bcl-2-gene. Blood 88:3937, 1996.
38 Stone R, Neuberg D, Soiffer R, Takvorian T, Whelan M, Rabinowe S,
Aster J, Leavitt P, Mauch P, Freedman A, Nadler L: Myelodysplastic syn-
drome as a late complication following autologous bone marrow trans-
plantation for non-Hodgkin’s lymphoma. J Clin Oncol 12:2535, 1994.
39 Miller J, Arthur D, Litz C, Neglia J, Miller W, Weisdorf D:
Myelodysplastic syndrome after autologous bone marrow transplanta-
tion: an additional late complication of curative cancer therapy. Blood
83:3780, 1994.
40 Darrington D, Vose J, Anderson J, Bierman P, Bishop M, Chan W,
Morris M, Reed E, Sanger WG, Tarantolo S, Weisenburger D, Kessinger A,
Armitage J: Incidence and characterization of secondary myelodysplas-
tic syndrome following high-dose chemoradiotherapy and autologous
stem-cell transplantation for lymphoid malignancies. J Clin Oncol
12:2527, 1994.
